These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 9408018)

  • 21. Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.
    Lusher JM; Scharrer I
    Int J Hematol; 2009 Nov; 90(4):446-454. PubMed ID: 19882376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS; Shapiro AD; Liesner RJ; Hernández Navarro F; Warrier I; Schroth PC; Spotts G; Ewenstein BM;
    J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan.
    Yoshioka A; Shima M; Fukutake K; Takamatsu J; Shirahata A;
    Haemophilia; 2001 May; 7(3):242-9. PubMed ID: 11380627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Arkin S; Rose E; Forster A; Aledort LM
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):47-51. PubMed ID: 1908129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
    Konkle BA; Stasyshyn O; Chowdary P; Bevan DH; Mant T; Shima M; Engl W; Dyck-Jones J; Fuerlinger M; Patrone L; Ewenstein B; Abbuehl B
    Blood; 2015 Aug; 126(9):1078-85. PubMed ID: 26157075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.
    Spira J; Plyushch OP; Andreeva TA; Andreev Y
    Blood; 2006 Dec; 108(12):3668-73. PubMed ID: 16888098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
    Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
    J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
    Manco-Johnson MJ; Kempton CL; Reding MT; Lissitchkov T; Goranov S; Gercheva L; Rusen L; Ghinea M; Uscatescu V; Rescia V; Hong W
    J Thromb Haemost; 2013 Jun; 11(6):1119-27. PubMed ID: 23528101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
    Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
    N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
    Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
    N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
    Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
    Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.
    Tiede A; Allen G; Bauer A; Chowdary P; Collins P; Goldstein B; Jiang HJ; Kӧck K; Takács I; Timofeeva M; Wolfsegger M; Srivastava S
    Haemophilia; 2020 Jan; 26(1):47-55. PubMed ID: 31778283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
    Gruppo RA; Brown D; Wilkes MM; Navickis RJ
    Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu V; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Sep; 33(9):1571-1578. PubMed ID: 28532239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.